The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Lutetium-179     lutetium

Synonyms: AC1L4ZTZ, 179Lu, 15755-89-2, Lutetium, isotope of mass 179
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of lutetium

  • Our purpose was to determine the feasibility of comprehensive treatment of the canine prostate with photodynamic therapy (PDT) using motexafin lutetium (Lu-Tex) and to evaluate the toxicity and tissue effects associated with this treatment [1].
  • In this study, the responsiveness of the heavily pigmented B16F10 murine melanoma to lutetium texaphyrin (PCI-0123), a water-soluble sensitizer with strong absorbance in the near infrared (700-760 nm), was examined [2].
  • Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer [3].
  • In vivo light dosimetry for motexafin lutetium-mediated PDT of recurrent breast cancer [4].
  • STUDY DESIGN/MATERIALS AND METHODS: We have treated 16 canines in preclinical studies, and 16 human subjects in a Phase I study, using motexafin lutetium-mediated PDT for recurrent prostate adenocarcinoma [3].
 

High impact information on lutetium

  • In particular we have followed the replacement of calcium by lutetium in bacterial recombinant oncomodulin and D59E oncomodulin to provide a measure of the protein's preferences for metal ions of different ionic radii [5].
  • Lu8Te and Lu7Te. Novel substitutional derivatives of lutetium metal [6].
  • Photoangioplasty with local motexafin lutetium delivery reduces macrophages in a rabbit post-balloon injury model [7].
  • Photodynamic therapy with motexafin lutetium (Lu-Tex) reduces experimental graft coronary artery disease [8].
  • PURPOSE: To examine the effect of combining angiostatin with photodynamic therapy (PDT) using Lutetium Texaphyrin (Lu-Tex; Alcon, Fort Worth, TX) as a photosensitizer in bovine retinal capillary endothelial (BRCE) and retinal pigment epithelial (RPE) cells and to determine the mode of PDT-induced cell death in these cell lines [9].
 

Biological context of lutetium

  • Lutetium induced the same structural changes in osteocalcin as calcium, but the two high-affinity Ca2+ binding sites did not have equal affinities for Lu3+ [10].
  • [reaction: see text] Ytterbium and lutetium ionic complexes derived from enantiopure substituted (R)-binaphthylamine ligands, of the general formula [Li(THF)(n)()][Ln[(R)-C(20)H(12)(NR)(2)](2)], have been investigated for the hydroamination/cyclization of several aminopentenes and an aminohexene [11].
  • We have investigated the pharmacokinetics (PK) of Lutetium Texaphyrin (Lu-Tex), a second-generation photosensitizer, in the Syrian hamster cheek pouch early cancer model [12].
  • The retention of the lutetium and the progress of the arthritis were followed for 47 days, and samples of the joint tissues were taken for histology at the end of the experiment [13].
  • In this ongoing trial, the primary objective is to determine the maximally tolerated dose of Motexafin lutetium-mediated PDT [14].
 

Anatomical context of lutetium

  • The effects of lutetium (Lu+++), europium (Eu+++) and neodymium (Nd+++) on 45Ca distribution, 45Ca movements and contractions were examined in rabbit aortic smooth muscle [15].
  • Lutetium (III) texaphyrin photosensitizes postirradiation or "delayed" photohemolysis (DPH) of human and bovine red blood cells at 730 nm by a Type-2 pathway mediated by singlet molecular oxygen [16].
  • The study also points out the importance of optimal labeling efficiency since the high bone marrow uptake of free lutetium ions can be controlled by a high peptide-bound fraction [17].
  • In vivo reflectance measurement of optical properties, blood oxygenation and motexafin lutetium uptake in canine large bowels, kidneys and prostates [18].
  • Fluorescence pharmacokinetics of Lutetium Texaphyrin (PCI-0123, Lu-Tex) in the skin and in healthy and tumoral hamster cheek-pouch mucosa [12].
 

Associations of lutetium with other chemical compounds

  • Three phase I studies are in progress, two using the beta-emitting radiometals yttrium 90 and lutetium 177, and a third using a cytotoxin (DM1) linked to J591 [19].
  • An X-ray crystal structure of 2 confirmed the ionic nature of the compound, with the cationic portion of the complex exhibiting a seven-coordinated lutetium center with trans-disposed iodo and alkoxide ligands and five pyridine molecules equally displaced within the equatorial plane [20].
  • The studied ions are Cl-, Br-, I-, ClO4-, NO3-, SCN-, and CH3COO-. The electrode assembly comprises a graphite electrode (GE) covered with a thin NB film containing a neutral strongly hydrophobic redox probe (decamethylferrocene or lutetium bis(tetra-tert-butylphthalocyaninato)) and an organic supporting electrolyte [21].
  • The combination of the motexafin lutetium and endovascular illumination, or Antrin phototherapy, has been shown to reduce plaque in animal models [22].
  • The redox properties of lutetium bis(tetra-tert-butylphthalocyaninato) (LBPC) have been studied in nitrobenzene that is deposited as a microfilm on the surface of highly oriented pyrolytic graphite electrodes [23].
 

Gene context of lutetium

  • Pigeon liver malic enzyme was inhibited by lutetium ion through a slow-binding process, which resulted in a concave down tracing of the enzyme activity assay [24].
  • Depletion of intracellular glutathione potentiated (P=0.035) and the addition of antioxidant N-acetylcysteine attenuated (P=0.002) cell death, suggesting that the intracellular redox state influences motexafin lutetium action [25].
 

Analytical, diagnostic and therapeutic context of lutetium

  • Preclinical evaluation of motexafin lutetium-mediated intraperitoneal photodynamic therapy in a canine model [26].
  • The composition evolution of the solution during the course of titration with lutetium was described, and the stepwise stability constants of complex formation, K(1):K(2) = 0.80 +/- 0.15 (K(1,2) > 10(8) M(-)(1)) and K(3) = (5.5 +/- 1) x 10(3) M(-)(1), were estimated [27].
  • Deep-UV Raman spectroscopy combined with chemometric analysis was shown to be a powerful tool for quantitative characterization of multiple equilibria between lutetium and a bicyclic diamide [27].
  • Lutetium speciation and toxicity in a microbial bioassay: testing the free-ion model for lanthanides [28].
  • A free ligand and its lutetium complexes showed weak, noncharacteristic near-UV absorption and no fluorescence, which limited the application of absorption and fluorescence spectroscopies for studying this system [27].

References

  1. Photodynamic therapy in the canine prostate using motexafin lutetium. Hsi, R.A., Kapatkin, A., Strandberg, J., Zhu, T., Vulcan, T., Solonenko, M., Rodriguez, C., Chang, J., Saunders, M., Mason, N., Hahn, S. Clin. Cancer Res. (2001) [Pubmed]
  2. Photodynamic therapy of B16F10 murine melanoma with lutetium texaphyrin. Woodburn, K.W., Fan, Q., Kessel, D., Luo, Y., Young, S.W. J. Invest. Dermatol. (1998) [Pubmed]
  3. Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer. Du, K.L., Mick, R., Busch, T.M., Zhu, T.C., Finlay, J.C., Yu, G., Yodh, A.G., Malkowicz, S.B., Smith, D., Whittington, R., Stripp, D., Hahn, S.M. Lasers in surgery and medicine. (2006) [Pubmed]
  4. In vivo light dosimetry for motexafin lutetium-mediated PDT of recurrent breast cancer. Dimofte, A., Zhu, T.C., Hahn, S.M., Lustig, R.A. Lasers in surgery and medicine. (2002) [Pubmed]
  5. Site-specific mutants of oncomodulin. 1H NMR and optical stopped-flow studies of the effect on the metal binding properties of an Asp59----Glu59 substitution in the calcium-specific site. Golden, L.F., Corson, D.C., Sykes, B.D., Banville, D., MacManus, J.P. J. Biol. Chem. (1989) [Pubmed]
  6. Lu8Te and Lu7Te. Novel substitutional derivatives of lutetium metal. Chen, L., Corbett, J.D. J. Am. Chem. Soc. (2003) [Pubmed]
  7. Photoangioplasty with local motexafin lutetium delivery reduces macrophages in a rabbit post-balloon injury model. Hayase, M., Woodbum, K.W., Perlroth, J., Miller, R.A., Baumgardner, W., Yock, P.G., Yeung, A. Cardiovasc. Res. (2001) [Pubmed]
  8. Photodynamic therapy with motexafin lutetium (Lu-Tex) reduces experimental graft coronary artery disease. Yamaguchi, A., Woodburn, K.W., Hayase, M., Hoyt, G., Robbins, R.C. Transplantation (2001) [Pubmed]
  9. Photodynamic therapy using Lu-Tex induces apoptosis in vitro, and its effect is potentiated by angiostatin in retinal capillary endothelial cells. Renno, R.Z., Delori, F.C., Holzer, R.A., Gragoudas, E.S., Miller, J.W. Invest. Ophthalmol. Vis. Sci. (2000) [Pubmed]
  10. Metal ion binding to dog osteocalcin studied by 1H NMR spectroscopy. Isbell, D.T., Du, S., Schroering, A.G., Colombo, G., Shelling, J.G. Biochemistry (1993) [Pubmed]
  11. Enantioselective intramolecular hydroamination catalyzed by lanthanide ate complexes coordinated by N-substituted (R)-1,1'-binaphthyl-2,2'-diamido ligands. Riegert, D., Collin, J., Meddour, A., Schulz, E., Trifonov, A. J. Org. Chem. (2006) [Pubmed]
  12. Fluorescence pharmacokinetics of Lutetium Texaphyrin (PCI-0123, Lu-Tex) in the skin and in healthy and tumoral hamster cheek-pouch mucosa. Zellweger, M., Radu, A., Monnier, P., van den Bergh, H., Wagnières, G. J. Photochem. Photobiol. B, Biol. (2000) [Pubmed]
  13. Effect of the intra-articular injection of lutetium-177 in chelator liposomes on the progress of an experimental arthritis in rabbits. Bard, D.R., Knight, C.G., Page-Thomas, D.P. Clinical and experimental rheumatology. (1985) [Pubmed]
  14. Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer. Verigos, K., Stripp, D.C., Mick, R., Zhu, T.C., Whittington, R., Smith, D., Dimofte, A., Finlay, J., Busch, T.M., Tochner, Z.A., Malkowicz, S., Glatstein, E., Hahn, S.M. J. Environ. Pathol. Toxicol. Oncol. (2006) [Pubmed]
  15. Interactions between several rare earth ions and calcium ion in vascular smooth muscle. Weiss, G.B., Goodman, F.R. J. Pharmacol. Exp. Ther. (1975) [Pubmed]
  16. Photosensitization of red blood cell hemolysis by lutetium texaphyrin. Bilgin, M.D., al Akhras, M.A., Khalili, M., Hemmati, H., Grossweiner, L.I. Photochem. Photobiol. (2000) [Pubmed]
  17. Biodistribution and dosimetry of 177Lu-labeled [DOTA0,Tyr3]octreotate in male nude mice with human small cell lung cancer. Schmitt, A., Bernhardt, P., Nilsson, O., Ahlman, H., Kölby, L., Schmitt, J., Forssel-Aronsson, E. Cancer Biother. Radiopharm. (2003) [Pubmed]
  18. In vivo reflectance measurement of optical properties, blood oxygenation and motexafin lutetium uptake in canine large bowels, kidneys and prostates. Solonenko, M., Cheung, R., Busch, T.M., Kachur, A., Griffin, G.M., Vulcan, T., Zhu, T.C., Wang, H.W., Hahn, S.M., Yodh, A.G. Physics in medicine and biology. (2002) [Pubmed]
  19. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Bander, N.H., Nanus, D.M., Milowsky, M.I., Kostakoglu, L., Vallabahajosula, S., Goldsmith, S.J. Semin. Oncol. (2003) [Pubmed]
  20. Auto-ionization in lutetium iodide complexes: effect of the Iioic radius on lanthanide-iodide binding. Giesbrecht, G.R., Gordon, J.C., Clark, D.L., Scott, B.L. Inorganic chemistry. (2004) [Pubmed]
  21. A comparative study of the anion transfer kinetics across a water/nitrobenzene interface by means of electrochemical impedance spectroscopy and square-wave voltammetry at thin organic film-modified electrodes. Gulaboski, R., Mirćeski, V., Pereira, C.M., Cordeiro, M.N., Silva, A.F., Quentel, F., L'Her, M., Lovrić, M. Langmuir : the ACS journal of surfaces and colloids. (2006) [Pubmed]
  22. Photodynamic therapy: applications in atherosclerotic vascular disease with motexafin lutetium. Chou, T.M., Woodburn, K.W., Cheong, W.F., Lacy, S.A., Sudhir, K., Adelman, D.C., Wahr, D. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. (2002) [Pubmed]
  23. Lutetium bis(tetra-tert-butylphthalocyaninato): a superior redox probe to study the transfer of anions and cations across the water|nitrobenzene interface by means of square-wave voltammetry at the three-phase electrode. Quentel, F., Mirceski, V., L'Her, M. The journal of physical chemistry. B, Condensed matter, materials, surfaces, interfaces & biophysical. (2005) [Pubmed]
  24. Slow binding of metal ions to pigeon liver malic enzyme: a general case. Hung, H.C., Chang, G.G., Yang, Z., Tong, L. Biochemistry (2000) [Pubmed]
  25. Photodynamic therapy with motexafin lutetium induces redox-sensitive apoptosis of vascular cells. Chen, Z., Woodburn, K.W., Shi, C., Adelman, D.C., Rogers, C., Simon, D.I. Arterioscler. Thromb. Vasc. Biol. (2001) [Pubmed]
  26. Preclinical evaluation of motexafin lutetium-mediated intraperitoneal photodynamic therapy in a canine model. Griffin, G.M., Zhu, T., Solonenko, M., Del Piero, F., Kapakin, A., Busch, T.M., Yodh, A., Polin, G., Bauer, T., Fraker, D., Hahn, S.M. Clin. Cancer Res. (2001) [Pubmed]
  27. Multiple Bicyclic Diamide-Lutetium Complexes in Solution: Chemometric Analysis of Deep-UV Raman Spectroscopic Data. Shashilov, V.A., Ermolenkov, V.V., Lednev, I.K. Inorganic chemistry. (2006) [Pubmed]
  28. Lutetium speciation and toxicity in a microbial bioassay: testing the free-ion model for lanthanides. Weltje, L., Verhoof, L.R., Verweij, W., Hamers, T. Environ. Sci. Technol. (2004) [Pubmed]
 
WikiGenes - Universities